Karen H. Lu, MD, on Next Steps in Evaluating Genetic Testing in Underrepresented Minorities


The MD Anderson Cancer Center expert discussed further research in delivering online accessible genetic testing.

There may still be a disconnect in women who are at risk for ovarian cancer to actually receive genetic testing, according to Karen H. Lu, MD.

At the 2020 ASCO Virtual Scientific Program, Lu – from the Department of Gynecologic Oncology and Reproductive Medicine at The University of Texas MD Anderson Cancer Center – presented on findings from the MAGENTA trial, designed to test whether pre and/or post-test genetic counseling is needed to optimally deliver online accessible genetic testing.

She spoke with CancerNetwork about next steps in this area of research.


One area that we that was really highlighted was we had wanted because the goal was to make this testing more accessible. We had really hoped to have a high minority population in rural population. And it turned out that that we did not fulfill that goal. And so I think a follow up would be to really focus on underrepresented minority populations and rural populations and focus to see if this form is helpful to that to those groups.

Related Videos
Interim data reveal favorable responses in patients with low-grade serous ovarian cancer treated with avutometinib plus defactinib, according to Susana N. Banerjee, MD.
Findings from the phase 3 MIRASOL trial support mirvetuximab soravtansine as a standard treatment option for platinum-resistant ovarian cancer, according to Ritu Salani, MD.
Trastuzumab deruxtecan appears to elicit ‘impressive’ responses among patients with HER2-positive gynecologic cancers regardless of immunohistochemistry in the phase 2 DESTINY-PanTumor02 trial.
Ritu Salani, MD, highlights the possible benefit of a novel targeted therapy and autologous tumor vaccine in patients with platinum-resistant ovarian cancer, and in the maintenance setting after treatment for platinum-sensitive disease.
In addition to potentially moving mirvetuximab into earlier lines of treatment for those with platinum-sensitive ovarian cancer, Ritu Salani, MD, also discusses combining the agent with carboplatin to decrease toxicities and improve quality of life.
Treatment with mirvetuximab soravtansine appears to produce a 3-fold improvement in objective response rate vs chemotherapy among patients with folate receptor-α–expressing, platinum-resistant ovarian cancer in the phase 3 MIRASOL trial.
Ritu Salani, MD, details the health-related quality of life benefits associated with dostarlimab in the treatment of advanced endometrial cancer, which includes improvements in back and pelvic pain.
Ritu Salani, MD, describes the concordance between blinded independent central review and provider-assessed outcomes with dostarlimab among patients with advanced recurrent endometrial cancer in the phase 3 RUBY trial.
Related Content